I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05986071 |
|
Recruitment Status :
Not yet recruiting
First Posted : August 14, 2023
Last Update Posted : March 29, 2024
|
Sponsor:
Institut Paoli-Calmettes
Collaborators:
National Cancer Institute, France
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Institut Paoli-Calmettes
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | April 1, 2027 |
| Estimated Study Completion Date : | October 15, 2027 |